• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

质子泵抑制剂对接受一线多西他赛联合治疗的中国初治转移性激素敏感性前列腺癌患者生存的影响。

Effect of Proton-Pump Inhibitor on Survival in Chinese Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer Receiving Upfront Combinatorial Docetaxel Treatment.

作者信息

Wong Chris Ho-Ming, Chiu Jamie Tsun, Ko Ivan Ching-Ho, Leung David Ka-Wai, Siu Brian, Cheng Cheuk-Kin Kevin, Lim Yung-Yung Joycelyn, Mok Hiu Tung, Kwok Chun-Fai Brian, Tang Cheuk Yi, Leung Steven Chi-Ho, Liu Kang, Chiu Peter Ka-Fung, Teoh Jeremy Yuen-Chun, Ng Chi Fai

机构信息

SH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China.

Department of Urology, Medical University of Vienna, 1090 Vienna, Austria.

出版信息

Cancers (Basel). 2025 Sep 1;17(17):2879. doi: 10.3390/cancers17172879.

DOI:10.3390/cancers17172879
PMID:40940975
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12427316/
Abstract

Prostate cancer is the second most commonly found malignancy for men worldwide, with its prevalence increasing with age [...].

摘要

前列腺癌是全球男性中第二常见的恶性肿瘤，其发病率随年龄增长而上升[……]。

相似文献

1
Effect of Proton-Pump Inhibitor on Survival in Chinese Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer Receiving Upfront Combinatorial Docetaxel Treatment.质子泵抑制剂对接受一线多西他赛联合治疗的中国初治转移性激素敏感性前列腺癌患者生存的影响。
Cancers (Basel). 2025 Sep 1;17(17):2879. doi: 10.3390/cancers17172879.
2
Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.雄激素受体信号抑制剂联合多西他赛与雄激素剥夺疗法治疗转移性激素敏感前列腺癌：系统评价和荟萃分析。
Eur Urol. 2022 Dec;82(6):584-598. doi: 10.1016/j.eururo.2022.08.002. Epub 2022 Aug 19.
3
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume.三药联合或两药联合治疗转移性激素敏感型前列腺癌：按疾病负荷分层的更新网络荟萃分析。
Eur Urol Focus. 2023 Sep;9(5):838-842. doi: 10.1016/j.euf.2023.03.024. Epub 2023 Apr 11.
4
Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer.达罗他胺：用于治疗转移性去势敏感性前列腺癌的药物。
Target Oncol. 2023 Sep;18(5):793-800. doi: 10.1007/s11523-023-00984-4. Epub 2023 Aug 5.
5
Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC.恩杂鲁胺与达罗他胺双重疗法在转移性去势敏感性前列腺癌中的匹配调整间接比较
Future Oncol. 2025 Aug;21(19):2459-2469. doi: 10.1080/14796694.2025.2526324. Epub 2025 Jul 14.
6
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis.三药联合或两药联合治疗转移性激素敏感型前列腺癌患者：系统评价和网络荟萃分析。
Eur Urol Focus. 2023 Jan;9(1):96-105. doi: 10.1016/j.euf.2022.08.007. Epub 2022 Sep 1.
7
Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis.三联疗法治疗转移性激素敏感前列腺癌的疗效与疾病负担的影响：系统评价、荟萃分析和网络荟萃分析。
Int J Clin Oncol. 2024 Jun;29(6):716-725. doi: 10.1007/s10147-024-02485-4. Epub 2024 Apr 6.
8
Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis.大体积转移性激素敏感型前列腺癌与小体积转移性激素敏感型前列腺癌患者全身治疗后的总生存：系统评价和网络荟萃分析。
Eur Urol Focus. 2022 Mar;8(2):399-408. doi: 10.1016/j.euf.2021.04.003. Epub 2021 Apr 11.
9
Treatment Landscape for Older Men With Metastatic Hormone-Sensitive Prostate Cancer in the United States.美国老年转移性激素敏感性前列腺癌男性患者的治疗概况
Cancer Med. 2025 Sep;14(17):e71176. doi: 10.1002/cam4.71176.
10
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.EAU 前列腺癌指南。第二部分：晚期、复发性和去势抵抗性前列腺癌的治疗。
Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.

本文引用的文献

1
Deep PSA response and extended time-to-nadir as robust predictors of survival in Asian patients with de novo metastatic hormone-sensitive prostate cancer receiving upfront intensified treatment.深度前列腺特异性抗原（PSA）反应和延长至最低点的时间，作为接受初始强化治疗的亚洲新发转移性激素敏感性前列腺癌患者生存的有力预测指标。
Prostate. 2025 Jan;85(1):30-39. doi: 10.1002/pros.24797. Epub 2024 Sep 19.
2
Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration-resistant prostate cancer patients.质子泵抑制剂对转移性去势抵抗性前列腺癌患者雄激素受体信号抑制剂疗效的影响。
Prostate. 2024 Oct;84(14):1329-1335. doi: 10.1002/pros.24769. Epub 2024 Jul 10.
3
Impact of comorbidities on prostate cancer-specific mortality: A population-based cohort study.
合并症对前列腺癌特异性死亡率的影响：一项基于人群的队列研究。
Prostate. 2024 Sep;84(12):1138-1145. doi: 10.1002/pros.24750. Epub 2024 May 26.
4
Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomized controlled trials.接受醋酸阿比特龙治疗的转移性前列腺癌患者同时使用质子泵抑制剂与生存率之间的关联：来自三项随机对照试验的汇总数据的事后分析
Prostate Cancer Prostatic Dis. 2024 Sep;27(3):444-450. doi: 10.1038/s41391-023-00695-x. Epub 2023 Jul 18.
5
2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review.2022 年前列腺癌流行病学和风险因素的更新：系统评价。
Eur Urol. 2023 Aug;84(2):191-206. doi: 10.1016/j.eururo.2023.04.021. Epub 2023 May 16.
6
The association between proton pump inhibitor use and systemic anti-tumour therapy on survival outcomes in patients with advanced non-small cell lung cancer: A systematic review and meta-analysis.质子泵抑制剂的使用与系统抗肿瘤治疗对晚期非小细胞肺癌患者生存结局的影响：系统评价和荟萃分析。
Br J Clin Pharmacol. 2022 Jul;88(7):3052-3063. doi: 10.1111/bcp.15276. Epub 2022 Mar 8.
7
Proton Pump Inhibitors and Oncologic Treatment Efficacy: A Practical Review of the Literature for Oncologists.质子泵抑制剂与肿瘤治疗疗效：肿瘤学家文献的实用综述。
Curr Oncol. 2021 Feb 3;28(1):783-799. doi: 10.3390/curroncol28010076.
8
The deleterious association between proton pump inhibitors and prostate cancer-specific mortality - a population-based cohort study.质子泵抑制剂与前列腺癌特异性死亡率之间的有害关联——一项基于人群的队列研究。
Prostate Cancer Prostatic Dis. 2020 Dec;23(4):622-629. doi: 10.1038/s41391-020-0248-9. Epub 2020 Jul 8.
9
Interaction between drugs and the gut microbiome.药物与肠道微生物组的相互作用。
Gut. 2020 Aug;69(8):1510-1519. doi: 10.1136/gutjnl-2019-320204. Epub 2020 May 14.
10
Duration of use of proton pump inhibitors and the risk of gastric and oesophageal cancer.质子泵抑制剂使用时间与胃癌和食管癌风险。
Cancer Epidemiol. 2019 Oct;62:101585. doi: 10.1016/j.canep.2019.101585. Epub 2019 Aug 21.